FGL2 and neoplasm: Although the concentration of antibody used has previously been shown to be effective in vivo 2,51,67, and we show significant targeting of FGL2 in the plasma following treatment and in the ascites, we did not conduct dose titration studies, so it is possible that the inability of α-FGL2 to enhance survival or reduce tumour burden might be due to low intra-tumoural concentration of the antibody.